Research
Molecular
The supramolecular GLP-1 receptor agonist (PA-GLP1) formulation achieved sustained serum concentrations for at least 40 days in a rat model of type 2 diabetes.
This formulation may provide a long-lasting treatment option for diabetes management.
StrongSupportsmedium confidence
In a rat model of type 2 diabetes, a single injection of the supramolecular PA-GLP1 formulation achieved sustained serum concentrations for at least 40 days.
Why this rating
Based on the use of a rat model to demonstrate sustained effects.
Source
Engineering Supramolecular Nanofiber Depots from a Glucagon-Like Peptide-1 Therapeutic
Weike Chen et al. · ACS Nano · 2024
DOI 10.1021/acsnano.4c10248
otherCited 6×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- The PA-GLP1 formulation resulted in an overall reduction in blood glucose levels and reduced weight gain compared to daily injections of semaglutide.Strong
- The engineered GLP-1 receptor agonist depot offers a more convenient and long-lasting therapeutic option for managing diabetes and treating metabolic disorders.Strong
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →